ArticleGland surgery2025
A nomogram for predicting the central lymph node metastasis in double primary carcinoma involving thyroid carcinoma.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the incidence of double primary carcinoma (DPC) involving thyroid carcinoma is clinically significant, current literature lacks sufficient investigation of this population, particularly regarding central lymph node metastasis (CLNM) patterns. Accurate preoperative prediction in CLNM is crucial for optimal surgical planning and decision-making. This study aimed to investigate the influential factors of CLNM in DPC involving thyroid carcinoma and develop a nomogram for the prediction in CLNM. Methods: A retrospective analysis of 62 cases with DPC involving thyroid carcinoma from January 2021 to May 2025 was performed. All patients presented with complete clinical data and underwent postoperative follow-up. Univariable and multivariable logistic regression analyses were used to identify the factors affecting CLNM. Based on the regression results, a nomogram model was constructed and internally validated using k-fold cross-validation. The C-index value, the calibration curve and the Hosmer-Lemeshow test were used to evaluate the performance of the model. Results: Analyses revealed that tumor size, tumor site, blood group and thyroglobulin (TG) were influential factors of CLNM in DPC involving thyroid carcinoma (P<0.05). These factors were incorporated into the construction of the nomogram [C-index =0.892, 95% confidence interval (CI): 0.878-0.906]. The sensitivity and specificity of the model were 75.0% and 91.3%. The k-fold cross-validation method (k=5) validated the high accuracy of the model (C-index =0.893). The model presented superior predictive power with a Hosmer-Lemeshow goodness-of-fit test value of χ Conclusions: Tumor size ≥0.95 cm and TG ≥15.62 mg/L were risk factors of CLNM in the DPC patients involving thyroid carcinoma. Meanwhile, lower tumor location in the thyroid and type B blood were risk factors of CLNM. The proposed nomogram could be a reliable tool for accurate prediction in CLNM. Additionally, our study showed that multifocal lung carcinoma patients always tended to have a higher rate of multifocality in thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.